Puma Biotechnology, Inc. (PBYI)

33.34
0.27 0.80
NASDAQ
Prev Close 33.61
Open 33.65
Day Low/High 33.07 / 33.86
52 Wk Low/High 17.60 / 83.15
Volume 159.57K
Exchange NASDAQ
Shares Outstanding 38.50B
Market Cap 1.31B
Div & Yield N.A. (N.A)

Latest News

Puma Biotechnology Expands Cohorts In Phase II SUMMIT Trial Of Neratinib In Cancer Patients With Tumors With Activating EGFR Or HER2 Mutations

Puma Biotechnology Expands Cohorts In Phase II SUMMIT Trial Of Neratinib In Cancer Patients With Tumors With Activating EGFR Or HER2 Mutations

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, has expanded two additional cohorts from the Phase II SUMMIT clinical trial investigating its lead drug candidate neratinib in patients with solid tumors who have an activating EGFR or...

Puma Biotechnology And Pierre Fabre Enter Into Exclusive License Agreement To Develop And Commercialize NERLYNX® (neratinib) In Europe

Puma Biotechnology And Pierre Fabre Enter Into Exclusive License Agreement To Develop And Commercialize NERLYNX® (neratinib) In Europe

Puma Biotechnology, Inc. (Nasdaq: PBYI) and Pierre Fabre have entered into an exclusive license agreement under which Pierre Fabre will develop and commercialize NERLYNX® (neratinib) within Europe and part of Africa.

Puma Biotechnology Announces Publication Of Abstracts On Neratinib For AACR Annual Meeting 2019

Puma Biotechnology Announces Publication Of Abstracts On Neratinib For AACR Annual Meeting 2019

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced publication of abstracts on neratinib for the American Association for Cancer Research (AACR) Annual Meeting 2019.

Puma Biotechnology Presents Interim Results From The Phase II SUMMIT Trial Of Neratinib For HER2 (ERBB2) Mutant, Metastatic Cervical Cancer At The Society Of Gynecologic Oncology (SGO) 2019 Annual Meeting

Puma Biotechnology Presents Interim Results From The Phase II SUMMIT Trial Of Neratinib For HER2 (ERBB2) Mutant, Metastatic Cervical Cancer At The Society Of Gynecologic Oncology (SGO) 2019 Annual Meeting

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced today that updated results from the cervical cancer cohort of SUMMIT, an ongoing Phase II basket trial examining the efficacy of neratinib in HER2-mutated cancers, were...

Puma Biotechnology's Licensing Partner Specialised Therapeutics Asia Receives Regulatory Approval To Commercialize NERLYNX® (neratinib) For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer

Puma Biotechnology's Licensing Partner Specialised Therapeutics Asia Receives Regulatory Approval To Commercialize NERLYNX® (neratinib) For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer

Puma Biotechnology, Inc. (Nasdaq: PBYI) announced that its licensing partner Specialised Therapeutics Asia (STA) has received marketing authorization from Australia's Therapeutic Goods Administration (TGA) to commercialize NERLYNX® (neratinib) in...

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on March 12, 2019 the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 30,688...

Puma Biotechnology To Present At Cowen's Annual Health Care Conference

Puma Biotechnology To Present At Cowen's Annual Health Care Conference

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H.

Puma Biotechnology Reports Fourth Quarter And Full Year 2018 Financial Results

Puma Biotechnology Reports Fourth Quarter And Full Year 2018 Financial Results

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2018.

April 12th Options Now Available For Puma Biotechnology (PBYI)

April 12th Options Now Available For Puma Biotechnology (PBYI)

Investors in Puma Biotechnology Inc saw new options become available today, for the April 12th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PBYI options chain for the new April 12th contracts and identified one put and one call contract of particular interest.

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on February 14, 2019 the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 16,375...

Puma Biotechnology To Host Conference Call To Discuss Fourth Quarter And Full Year Financial Results

Puma Biotechnology To Host Conference Call To Discuss Fourth Quarter And Full Year Financial Results

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.

PBYI March 29th Options Begin Trading

PBYI March 29th Options Begin Trading

Investors in Puma Biotechnology Inc saw new options become available today, for the March 29th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PBYI options chain for the new March 29th contracts and identified one put and one call contract of particular interest.

Puma Biotechnology Announces Litigation Victory With Jury's Decision

Puma Biotechnology Announces Litigation Victory With Jury's Decision

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced today that the class action lawsuit, Hsu vs.

Interesting PBYI Put And Call Options For March 22nd

Interesting PBYI Put And Call Options For March 22nd

Investors in Puma Biotechnology Inc saw new options begin trading today, for the March 22nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PBYI options chain for the new March 22nd contracts and identified one put and one call contract of particular interest.

Puma Biotechnology And Knight Therapeutics Enter Into Exclusive License Agreement To Commercialize NERLYNX® (neratinib) In Canada

Puma Biotechnology And Knight Therapeutics Enter Into Exclusive License Agreement To Commercialize NERLYNX® (neratinib) In Canada

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that it has entered into an exclusive License Agreement with Knight Therapeutics Inc.

First Week Of February 8th Options Trading For Puma Biotechnology (PBYI)

First Week Of February 8th Options Trading For Puma Biotechnology (PBYI)

Investors in Puma Biotechnology Inc saw new options become available this week, for the February 8th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PBYI options chain for the new February 8th contracts and identified one put and one call contract of particular interest.

Puma Biotechnology To Present At J. P. Morgan Healthcare Conference

Puma Biotechnology To Present At J. P. Morgan Healthcare Conference

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H.

February 22nd Options Now Available For Puma Biotechnology (PBYI)

February 22nd Options Now Available For Puma Biotechnology (PBYI)

Investors in Puma Biotechnology Inc saw new options become available today, for the February 22nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PBYI options chain for the new February 22nd contracts and identified one put and one call contract of particular interest.

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on December 30, 2018 the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 10,750...

Puma Biotechnology Announces Top Line Results Of The Phase III NALA Trial Of Neratinib In Patients With HER2-Positive Metastatic Breast Cancer

Puma Biotechnology Announces Top Line Results Of The Phase III NALA Trial Of Neratinib In Patients With HER2-Positive Metastatic Breast Cancer

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced top line results from the Phase III NALA trial of the Company's lead drug candidate PB272 (neratinib) in patients with HER2-positive metastatic breast cancer who have failed...

Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that in connection with the appointment of Maximo F.

Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that in connection with the appointment of Maximo F.

Puma - CONTROL Poster At SABCS 2018

Puma - CONTROL Poster At SABCS 2018

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, is presenting updated results from a Phase II clinical trial of Puma's drug neratinib at the 2018 San Antonio Breast Cancer Symposium (SABCS) that is currently taking place in San...

Puma - SUMMIT Poster At SABCS 2018

Puma - SUMMIT Poster At SABCS 2018

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that results from an ongoing Phase II clinical trial of Puma's drug neratinib are being presented at the 2018 San Antonio Breast Cancer Symposium (SABCS) that is currently...

Puma - ExteNET Poster At SABCS 2018

Puma - ExteNET Poster At SABCS 2018

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that results from the subgroup of patients with hormone receptor positive (HR-positive) breast cancer from the Company's Phase III ExteNET Trial of neratinib for early stage...

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on December 2, 2018 the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 44,875...

PBYI January 2019 Options Begin Trading

PBYI January 2019 Options Begin Trading

Investors in Puma Biotechnology Inc saw new options become available today, for the January 2019 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PBYI options chain for the new January 2019 contracts and identified one put and one call contract of particular interest.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BERY, DLTH, DNB, ETSY, LND, MOS Downgrades: CIZN, CVV, FCX, LIND, OAS, PACW, PTVCB, STN, SYF, WAFD Initiations: CSSE, PBYI, PVG, SMPL, TRMT Read on to get TheStreet Quant Ratings' detailed report:

TheStreet Quant Rating: D- (Sell)